190A Chordia Therapeutics
- 301
- -24-7.38%
Chordia Therapeutics News
Chordia Therapeutics: Announcement of Presentation on Phase 1 Clinical Trial of CLK Inhibitor CTX-712 at the 86th Annual Meeting of the Japanese Society of Hematology
Chordia Therapeutics: Abstracts relating to the Phase 1 clinical trial of the CLK inhibitor CTX-712 were selected at the 86th Annual Meeting of the Japanese Society of Hematology
Chordia Therapeutics: Change report.
Chordia Therapeutics: Notice regarding financial results announcements and financial results briefings for the fiscal year ending 2024/8
Chordia Therapeutics: Change Report
Change report.
Chordia Therapeutics: Mass Ownership Report
Chordia Therapeutics: Participation in the company briefing for individual investors hosted by the Sapporo Stock Exchange.
Chordia Therapeutics: Change Report
Chordia Therapeutics: Change report.
Change Report
Chordia Therapeutics: Chordia won the Minister of Education, Culture, Sports, Science and Technology Award at the Japan Startup Awards 2024.
Chordia Therapeutics: Chordia won the Minister of Education, Culture, Sports, Science and Technology Award at the Japan Startup Awards 2024.
Chordia Therapeutics: Confirmation letter
Chordia Therapeutics: Quarterly Report - 7th Quarter 3rd Quarter (2024/03/01 - 2024/05/31)
Chordia Therapeutics: Third quarter financial results for August 2024 term, based on Japanese standards (non-consolidated).
Chordia Therapeutics: Unconsolidated financial results [Japan standard] for the nine months ended May 31, 2024.
Chordia Therapeutics: Announcements of individual stock regarding the results of third-party allocation of capital increase.
Chordia Therapeutics: Exhibited at the 19th Nikkei IR and Individual Investor Fair in 2024.
Chordia Therapeutics: Received the Mizuho Innovation Award 2024.2Q, which was sponsored by Mizuho Bank.
Analysis
Price Target
No Data
No Data